T1	intervention 0 26	Bisphosphonate risedronate
T2	condition 36 45	bone loss
T3	eligibility 49 117	women with artificial menopause due to chemotherapy of breast cancer
T4	total-participants 413 424	Fifty-three
T5	ethinicity 425 430	white
T6	age 443 457	36 to 55 years
T8	intervention-participants 694 696	27
T9	control 701 708	placebo
T7	control-participants 714 716	26
T12	outcome 1291 1300	bone loss
T11	outcome 1598 1617	at the femoral neck
T13	outcome 1660 1681	at the hip trochanter
T14	outcome 1802 1816	well tolerated
T15	outcome 1835 1849	safety profile
T16	outcome 1871 1895	laboratory abnormalities
T17	outcome 1157 1188	BMD at the lumbar spine and hip
T18	outcome 1236 1239	BMD
T10	outcome-Measure 955 997	changes in lumbar spine and proximal femur
T19	outcome-Measure 1046 1072	bone mineral density (BMD)
T20	outcome-Measure 1078 1114	biochemical markers of bone turnover
